Ipca Laboratories Ltd (IPCALAB)

Analysts Upgrade Ipca Laboratories Ltd Amidst Pharma Sector Upgrades - 16 Jul, 2024

Ipca Laboratories Ltd has been upgraded by analysts amidst consistent upgrades in the pharma sector. Analysts recommend playing the turnaround in cycles and remaining invested through the up cycle.

Ipca Laboratories Ltd Up for Third Straight Session - 05 Jul, 2024

Ipca Laboratories Ltd gained 1.04% to Rs 1190.05 on the NSE, while the Nifty Pharma index rose 1.37%. The stock has gained 2.44% in the last month and is up 56.58% YoY. The PE of the stock is 48.43 based on TTM earnings ending March 24.

HDFC Securities Suggests Buying IPCA Laboratories - 03 Jul, 2024

HDFC Securities recommends buying shares of IPCA Laboratories with a target price of Rs 1,240 and a second target of Rs 1,305. The stock closed 2.2% higher at Rs 1,156.4 each on July 3, indicating potential returns of 13%. Maintain stop loss at Rs 680 and Rs 1,080.

Ipca Labs Subsidiary Fined for Patent Dispute - 28 Jun, 2024

Unichem Laboratories, a subsidiary of Ipca Labs, has been fined Rs 126 crore by the EU Court for a patent dispute with French company Servier group. The company has made provisions in its financial records but stated that it would have no material impact on operations. Additionally, Ipca Labs' ROE is lower than the industry average, and its five-year net income has declined.

Ipca Laboratories Clarifies Fine Imposed on Unichem Subsidiary - 27 Jun, 2024

Ipca Laboratories has clarified that the fine imposed on Unichem Laboratories and its subsidiary, Niche Generics, will not have a material impact on its operations as provisions totalling ₹125.62 crore have already been made in its accounts to cover litigation costs.

Ipca Laboratories Stock Expected to Resume Uptrend - 22 Jun, 2024

After falling below the ₹1,360 barrier, Ipca Laboratories stock is finding support at around ₹1,130 with a potential uptrend resuming within the ₹1,050-1,130 price band.

Ipca Labs Q4 FY24 Net Sales Up 34.49% YoY - 18 Jun, 2024

Ipca Laboratories reported a 34.49% YoY increase in net sales for Q4 FY24, with EBITDA up by 56.75%. However, quarterly net profit decreased by 22.12% YoY and EPS decreased from Rs. 3.02 to Rs. 2.35. The stock has given returns of 6.97% over the last 6 months and 64.80% over the last 12 months.